Melanotan II

Melanotan II does not have an approved clinical dosing label. Published early human research has evaluated Melanotan II in controlled study settings, including subcutaneous exposure measured by body weight. One early clinical study discussed a 0.025 mg/kg dose and reported nausea and yawning as frequent side effects, with severe nausea reported in a portion of subjects at that level. Because this compound is not approved for routine clinical use, published study figures should be treated as research-context references only, not as personal dosing instructions or recommended use.

Researcher-reported exploratory Melanotan II ranges commonly discuss very small sub-milligram quantities, often around 250-500 mcg per exposure in cautious experimental models, with some non-clinical discussions extending toward 1 mg depending on study design, response markers, and endpoint being observed. These ranges are not validated clinical protocols. Protocol design depends on the study model, receptor-pathway target, pigmentation or neuroendocrine endpoint, route, concentration, exposure schedule, and safety controls.

For storage and handling, Melanotan II should follow standard peptide-integrity practices. Store unopened lyophilized vials refrigerated when possible and protected from direct light, heat, and repeated temperature changes. Once reconstituted, keep refrigerated and avoid unnecessary warming, freezing, or repeated agitation. If mixing is needed after adding diluent, gently swirl the vial rather than shaking it. Aggressive shaking can create foaming and may reduce peptide integrity over time.